KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Amortization - Intangibles (2016 - 2017)

Historic Amortization - Intangibles for Teva Pharmaceutical Industries (TEVA) over the last 6 years, with Q4 2016 value amounting to $170.0 million.

  • Teva Pharmaceutical Industries' Amortization - Intangibles fell 1237.11% to $170.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $876.0 million, marking a year-over-year decrease of 1274.9%. This contributed to the annual value of $170.0 million for FY2016, which is 1237.11% down from last year.
  • According to the latest figures from Q4 2016, Teva Pharmaceutical Industries' Amortization - Intangibles is $170.0 million, which was down 1237.11% from $194.0 million recorded in Q4 2015.
  • In the past 5 years, Teva Pharmaceutical Industries' Amortization - Intangibles registered a high of $298.0 million during Q4 2013, and its lowest value of $170.0 million during Q4 2016.
  • For the 5-year period, Teva Pharmaceutical Industries' Amortization - Intangibles averaged around $244.9 million, with its median value being $268.0 million (2014).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Amortization - Intangibles surged by 996.31% in 2013, and later tumbled by 2049.18% in 2015.
  • Over the past 5 years, Teva Pharmaceutical Industries' Amortization - Intangibles (Quarter) stood at $271.0 million in 2012, then increased by 9.96% to $298.0 million in 2013, then dropped by 18.12% to $244.0 million in 2014, then fell by 20.49% to $194.0 million in 2015, then fell by 12.37% to $170.0 million in 2016.
  • Its last three reported values are $170.0 million in Q4 2016, $194.0 million for Q4 2015, and $244.0 million during Q4 2014.